NCT01584141

Brief Summary

Background: \- Lymphoma rates in Asia have been lower than in the West, but rates have been rising in recent years. Most studies of lymphoma patients have been conducted in the West. Less information is available about the factors that might contribute to the rise of lymphoma in Asia. Researchers want to collect medical and personal histories and samples from people who have recently been diagnosed with lymphoma. This information will help them study possible reasons for this increase. Objectives: \- To collect samples and histories as part of an introductory study of lymphoma in Asia. Eligibility:

  • People between 18 and 79 years of age who have entered study hospitals in Hong Kong, Taiwan, and mainland China for treatment for any type of lymphoma.
  • Healthy volunteers between 18 and 79 who have never had lymphoma. Design:
  • Participants will be screened with a physical exam and medical history.
  • They will provide blood samples and cheek cell samples for testing.
  • Participants will complete a questionnaire about their personal health history. They will answer questions about exposures to chemicals like pesticides. They will also be asked about family medical history and work and residential history. Finally they will answer questions about lifestyle factors like diet and exercise.
  • They will give permission for the researchers to see their medical records. Researchers will also have access to any tumor samples collected as part of treatment.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13,433

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2011

Longer than P75 for all trials

Geographic Reach
3 countries

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 5, 2011

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 24, 2012

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 10, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 10, 2018

Completed
Last Updated

November 27, 2020

Status Verified

November 1, 2020

Enrollment Period

7 years

First QC Date

April 21, 2012

Last Update Submit

November 24, 2020

Conditions

Lymphoma, FollicularLymphoma, Non-HodgkinMultiple MyleomaLympocytic, FollicularLeukemiaHodgkin Lymphoma

Keywords

LeukemiaLymphomaOccupational EpidemiologyMolecular EpidemiologyGenetic Polymorphisms

Outcome Measures

Primary Outcomes (2)

  • Evaluation of chemical exposures and genetic susceptibility

    A large-scale evaluation of genes associated with lymphoma in Asian populations that parallels efforts being conducted in Caucasian populations (e.g., currently a genome-wide association study (GWAS)) would be particularly informative because of Asian population genetic differences in patterns of LD and local haplotype structure.

    2020

  • Explore relationship between other factors (viral infections, UV exposure, medical conditions, and lifestyle factors and non-Hodgkin Lymphoma

    Other factors potentially related to NHL, such as viral infections, UV exposure, medical conditions, and other lifestyle factors will also beexplored.

    2020

Study Arms (2)

Cases

Asian cases with lymphoid or myeloid neoplasma

Controls

Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The population of this study are Asian cases with lymphoid or myeloid neoplasma and controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan.@@@

You may qualify if:

  • Eligible cases will be patients at a participating hospital who are between 18 and 79 years of age at time of initial diagnosis and admitted or treated with incident diagnoses of any lymphoid or myeloid neoplasm including all NHL and Hodgkin disease. Although it is important to understand the etiology of lymphoma in children as well, this undertaking would require additional hospitals, instruments, expertise, and funding that are not currently available to our research team. Adults over the age of 80 are generally among the sickest patients in the hospital and often have multiple comorbidities, which may preclude their participation in an interview of this length. Cases will be permanent residents of the general geographic region that is served by the hospital at the time of diagnosis. Cases will include chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, plasmacytoma, multiple myeloma, aggressive NK cell leukemia, cutaneous lymphomas, myeloid neoplasms, and immunosuppression-associated cases (such as HIV, post transplant, Methotrexate use).
  • ,400 lymphoid neoplasm cases will be enrolled with less common subtypes in Asian populations including Hodgkin disease, multiple myeloma, chronic lymphocytic leukemia, and NK/T, T, follicular and marginal zone lymphoma, in order to increase statistical power to study risk factors for these tumors.

You may not qualify if:

  • Cases with previous diagnosis of lymphoma, such as acute lymphoblastic lymphoma, multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma, are ineligible.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Tianjin Medical University Cancer Institute & Hospital

Hexi District, 300060, China

Location

West China Hospital of Sichuan University

Sichuan, 610041, China

Location

Queen Mary Hospital

Sai Ying Pun, Hong Kong

Location

Buddhis Dalin Tzu Chi General Hospital

Dalin Town, Taiwan

Location

Related Publications (2)

  • Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, Ricker W, Parsons R, Wheeler W, Engels EA. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3069-75. doi: 10.1158/1055-9965.EPI-08-0408. Epub 2008 Oct 28.

    PMID: 18957521BACKGROUND

  • Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Suefuji N, Kikuchi M, Ohshima K. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int. 2008 Mar;58(3):174-82. doi: 10.1111/j.1440-1827.2007.02207.x.

    PMID: 18251781BACKGROUND

MeSH Terms

Conditions

Lymphoma, FollicularLymphoma, Non-HodgkinLeukemiaHodgkin DiseaseLymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesHematologic Diseases

Study Officials

  • Qing Lan, M.D.

    National Cancer Institute (NCI)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2012

First Posted

April 24, 2012

Study Start

July 5, 2011

Primary Completion

July 10, 2018

Study Completion

July 10, 2018

Last Updated

November 27, 2020

Record last verified: 2020-11

Locations

CN(2)HK(1)TW(1)